Gotham Asset Management LLC Has $890,000 Stock Holdings in Alkermes plc (NASDAQ:ALKS)

Gotham Asset Management LLC lessened its position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 73.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 30,937 shares of the company's stock after selling 83,983 shares during the period. Gotham Asset Management LLC's holdings in Alkermes were worth $890,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. CIBC Asset Management Inc raised its stake in Alkermes by 4.4% during the fourth quarter. CIBC Asset Management Inc now owns 9,155 shares of the company's stock valued at $263,000 after buying an additional 384 shares in the last quarter. O Shaughnessy Asset Management LLC grew its holdings in Alkermes by 3.9% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 14,203 shares of the company's stock worth $408,000 after buying an additional 532 shares in the last quarter. Sei Investments Co. grew its holdings in Alkermes by 1.1% in the 4th quarter. Sei Investments Co. now owns 75,394 shares of the company's stock worth $2,168,000 after buying an additional 828 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Alkermes by 106.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company's stock worth $47,000 after buying an additional 842 shares in the last quarter. Finally, Venturi Wealth Management LLC bought a new position in Alkermes during the 4th quarter valued at $25,000. Hedge funds and other institutional investors own 95.21% of the company's stock.

Analyst Ratings Changes

A number of brokerages have issued reports on ALKS. Robert W. Baird increased their price target on Alkermes from $38.00 to $41.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Royal Bank of Canada upped their price target on shares of Alkermes from $39.00 to $40.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd. Deutsche Bank Aktiengesellschaft increased their target price on shares of Alkermes from $40.00 to $52.00 and gave the stock a "buy" rating in a research report on Thursday, March 27th. HC Wainwright reissued a "neutral" rating on shares of Alkermes in a research report on Friday, May 2nd. Finally, Wall Street Zen downgraded Alkermes from a "strong-buy" rating to a "buy" rating in a research report on Monday, May 5th. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Alkermes presently has a consensus rating of "Moderate Buy" and a consensus price target of $38.33.

Alkermes Stock Performance

ALKS traded down $0.70 during trading on Friday, reaching $29.35. 2,005,528 shares of the company's stock were exchanged, compared to its average volume of 1,758,838. The company's fifty day moving average price is $30.23 and its 200-day moving average price is $30.81. Alkermes plc has a fifty-two week low of $22.90 and a fifty-two week high of $36.45. The firm has a market capitalization of $4.84 billion, a PE ratio of 13.53, a P/E/G ratio of 2.20 and a beta of 0.51.

Alkermes (NASDAQ:ALKS - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $0.13 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.19). Alkermes had a return on equity of 30.80% and a net margin of 23.57%. The company had revenue of $306.51 million during the quarter, compared to analyst estimates of $307.53 million. During the same period in the previous year, the company posted $0.43 earnings per share. Alkermes's revenue for the quarter was down 12.6% on a year-over-year basis. Research analysts forecast that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.